Full Breakdown
Gilead’s Oral Ulcerative Colitis Pill Meets Mid-Stage Goal
By Drooid · · How we work
Trial Results
On October 19, 2026 Gilead Sciences announced that its Phase 2 “SWIFT” trial of emvistegrast (GS-1427) met its primary endpoint. In the 200 mg cohort, 66 % of participants achieved a clinical response at Week 12, compared with 37 % on placebo. Clinical remission was observed in 31 % of treated patients versus 8 % with placebo.
Data Highlights
The trial enrolled 238 adults with moderate-to-severe ulcerative colitis and tested three oral doses (200 mg, 75 mg, 25 mg). Response rates fell to 51 % and 43 % for the 75 mg and 25 mg arms, respectively. Remission rates for those lower doses were 20 % and 9 %. Secondary endpoints—including mucosal healing and endoscopic improvement—showed a similar pattern, with the 75 mg dose underperforming the 25 mg dose. Gilead described the dose-response variability as “potential study noise” and noted the small arm sizes.
Diversification Context
Ulcerative colitis represents a strategic expansion beyond Gilead’s HIV-centric portfolio, which generated $5.7 billion of the company’s $7.8 billion total sales in the most recent quarter. Recent diversification moves include a $7.8 billion acquisition of CAR-T collaborator Arcellx, equity stakes in Vir Biotechnology, and partnerships with Ouro Medicines and Tubulis.
Official Statements & Responses
Swati Tole, senior vice president of Clinical Development, Inflammation, said the company will advance emvistegrast into a Phase 3 program slated to begin next year and is exploring combination-therapy options. Gilead also noted that the trial’s safety profile was generally well tolerated during the induction phase.
Verbatim Quotes
- “Despite an uneven dose response, we see the data as encouraging clinical POC [proof of concept] for emvistegrast and another step in GILD’s broader I&I ambitions,” — Truist
